Spesolimab treatment in 2 cases of generalized pustular psoriasis following COVID-19 and corticosteroid withdrawal
JAAD Case Reports · 2026-12 · 78 · 122-127
DOI: 10.1016/j.jdcr.2026.07.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAAD Case Reports, 2026-12. Verfasst von Kateryna Karpoff und 3 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: LEO Pharma Research Foundation.
Abstract (Originalsprache)
Generalized pustular psoriasis (GPP) is a rare, systemic autoinflammatory dermatosis with life-threatening potential and worldwide mortality rates of 2% to 7%.1,2 It is characterized by widespread erythema and macroscopically visible sterile pustules that may coalesce into “lakes of pus.” GPP is linked to aberrant interleukin (IL)-36 signaling, often through IL36RN mutations causing IL-36-receptor antagonist deficiency.3 However, not all patients harbor IL36RN mutations, reflecting disease heterogeneity.
Förderung
- LEO Pharma Research Foundation
Zitieren
APA
Karpoff, K., Guénin, S., Paul, K., & Lebwohl, M. G. (2026). Spesolimab treatment in 2 cases of generalized pustular psoriasis following COVID-19 and corticosteroid withdrawal. JAAD Case Reports, 78, 122-127. https://doi.org/10.1016/j.jdcr.2026.07.034
Vancouver
Karpoff K, Guénin S, Paul K, Lebwohl MG. Spesolimab treatment in 2 cases of generalized pustular psoriasis following COVID-19 and corticosteroid withdrawal. JAAD Case Reports. 2026;78:122-127. doi:10.1016/j.jdcr.2026.07.034
BibTeX
@article{Karpoff2026,
author = {Karpoff, Kateryna and Guénin, Sophie and Paul, Kevin and Lebwohl, Mark G.},
title = {Spesolimab treatment in 2 cases of generalized pustular psoriasis following COVID-19 and corticosteroid withdrawal},
journal = {JAAD Case Reports},
year = {2026},
volume = {78},
pages = {122--127},
doi = {10.1016/j.jdcr.2026.07.034}
}
EUVIMED